Laurence Bary
Dechert (Paris)
Partner
Laurence Bary is an antitrust lawyer in the Paris office of Dechert. Her practice focuses on EU and French competition law, including merger control, cartel investigations, market dominance cases and related litigation matters. She advises international clients in large merger control cases before the European Commission, including Phase 2 cases, and represented clients in a number of international cartel/dominance investigations, including several recent investigations in the technology sector. She has extensive experience of litigation both before the European courts in Luxembourg and the French courts, including representing high-profile companies in follow-on damage actions in France. Laurence Bary is a graduate of the Ecole Normale Supérieure and Sciences-Po Paris.
Distinctions
Linked authors
Frédéric de Bure
Cleary Gottlieb Steen & Hamilton (Paris)
Mélanie Thill-Tayara
Dechert (Paris)
Isabelle de Silva
French Competition Authority (Paris)
Laurent Flochel
CRA International (Paris)
Etienne Chantrel
French Competition Authority (Paris)
Elizabeth Kraus
US Federal Trade Commission (FTC) (Washington)
Birthe Panhans
DG COMP (Brussels)
Alec J. Burnside
Dechert (Brussels)
2594 | Conferences
Videos
Articles
96 Bulletin
96
The General Court of the European Union recently held, in Goldman Sachs v. Commission, that purely financial investors such as investment funds may be held jointly and severally liable for competition law violations implemented by their portfolio companies when they can exercise “decisive (...)
2281 Review
192
The present contributions were gathered following up the 10th edition of the “New Frontiers of Antitrust” annual Concurrences review Conference held in Paris on June 14th, 2019, at the French Ministry of Economy and Finance. The discussions revolved around four topics. The members of the first (...)
1145
Common ownership has become a hot topic in antitrust. Until recently, though, it remained largely a theoretical debate. The merger control decisions issued by the European Commission in Dow/DuPont and Bayer/Monsanto, however, have suddenly made it a real concern for companies – even though the (...)
945
Innovation seems to have become the new mantra among the antitrust community in Europe. In the specific context of merger control, the debate focuses on the possible impact of mergers on classic R&D and whether turnover-based jurisdictional thresholds create a risk that certain harmful (...)
